A total of @ patients with a spectrum of coronary artery disease will undergo prospective , random assignment to a Orsiro Hybrid sirolimus-eluting stent or Resolute Integrity zotarolimus-eluting stent ( @:@ ratio ) , for a primary endpoint of in-stent late lumen loss at @ months by quantitative coronary angiography .